dRx Capital

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

<div>
 
 Freenome is a California-based biotechnology company that focuses on developing tests for early cancer detection using a routine blood draw. The genetic profiling startup has developed a machine learning and AI-powered multiomics platform that was built on thousands of cancer-positive samples, allowing it to learn which biomarker pattern signifies a type of cancer. While most competitors rely only on tumor-derived markers, Freenome&rsquo;s platform detects key biological signals beyond mutations that are early warning signs for cancer, incorporating both tumor and non-tumor-derived indicators which support early detection.&nbsp;
 
 
 The platform analyzes an individual&rsquo;s cell-free DNA, methylation (RNA processing), and proteins to gain insights into immune response, tumor heterogeneity, and gene expression changes in the body associated with tumor formation. As of January 2022, the company was carrying out a study, known as the PREEMPT CRC clinical trial, to develop a blood test for the early detection of colorectal cancer (CRC). The company was also looking to enroll 25,000 participants for a study to validate its blood test and to support its submission for approval by the US Food and Drug Administration. Its CRC screening test integrates personalized clinical insights with health systems via more than 100 healthcare partnerships across the US.&nbsp;
 
 
 The company is also extending its multiomics platform with biomarkers for other cancer types, including pancreatic cancer and breast cancer. It plans to launch additional multi-cancer clinical studies in February 2022, focused on personalized screening tests based on an individual&rsquo;s risk.&nbsp;
 
 
 In May 2023, Freenome 
 <a href="https://sp-edge.com/updates/18782">
 acquired Oncimmune 
 </a>
 for a total consideration of GBP 13 million (~USD 16.1 million). The acquisition provides Freenome with additional clinical and commercial resources, including a pipeline of autoantibody targets for cancer indications.
 
 
 Key customers and partnerships
 
 
 <a href="https://sp-edge.com/updates/19455">
 In June 2023
 </a>
 , Freenome and Walgreens entered a multi-year partnership to advance clinical studies focused on the early detection of cancer through the use of Freenome's blood-based tests.
 
 
 Funding and Financials
 
 
 In January 2022, the company surpassed USD 1 billion in funding after receiving an investment from Roche amounting to USD 290 million, which was used to advance its CRC screening test and expansion of its multiomics platform to other cancers.
 
</div>

<div>
 
 COTA Healthcare is a bioinformatics startup that provides real-world data and analytics solutions focused on cancer care. COTA&rsquo;s platform uses data from a wide range of data sources, including electronic health records, clinical trials, and patient registries. Through its proprietary technology and analytics, COTA organizes and analyzes this data to offer insights into patient outcomes, treatment effectiveness, and the cost-effectiveness of various treatments. These insights have the potential to enhance patient care, expedite drug development, and guide policy decisions.
 
 
 
 
 The firm offers six different services to cater to the diverse needs of its target audience. These offerings encompass real-world data analytics, data abstraction and curation, as well as data consulting and advisory services. Operating as a B2B entity, COTA collaborates with pharmaceutical companies, academic institutions, healthcare providers, and health plans. As of May 2023, the company had over 2 million individuals diagnosed with cancer and more than 1,500 providers in its network.&nbsp;
 
 
 Key customers and partnerships
 
 
 In March 2021, the company partnered with Kite, a Gilead company, through which COTA&rsquo;s real-world data would be used to accelerate Kite&rsquo;s drug development pipeline. The company partnered with molecular testing company Genomic Testing Cooperative (GTC) in March 2023&nbsp; to combine COTA&rsquo;s clinical oncology real-world data with GTC&rsquo;s genomics testing data to support precision medicine-based care delivery. The company has also partnered with leading cancer organizations, including the American Cancer Society, the National Cancer Institute, and the Dana-Farber Cancer Institute.
 
 
 Funding and financials
 
 
 The company&rsquo;s most recent funding round was in October 2022, where it raised an unspecified amount in a Series E funding round led by Deerfield Management. The funds were used to accelerate and further diversify COTA's oncology real-world data products and services. 
 
 
 
</div>

<div>
 
 SomaLogic is a proteomics company offering protein biomarker discovery and clinical diagnostics services to support drug development and precision medicine. Its proprietary SomaScan platform can measure 7,000 proteins in the human body, with plans to reach 10,000 by 2023.&nbsp;
 
 
 The company provides two core services - SomaScan Discovery for large-scale protein detection and SomaSignal Tests which analyze patient samples for disease risk assessment. SomaSignal leverages a bioinformatics algorithm built on over 450,000 protein samples. To enhance its proteomics capabilities, SomaLogic acquired DNA nanotechnology firm 
 <a href="https://sp-edge.com/updates/11889">
 Palamedrix
 </a>
 in 2022 for its technology to improve SomaScan's accessibility and usage. The company&rsquo;s technology is built on two decades of research and development, and, as of November 2022, had over 600 patents covering areas such as chemistry, data analytics, diagnostics, and therapeutic.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company had entered into several strategic collaborations in private and public entities for drug discovery and development including a 10-year agreement with 
 <a href="https://sp-edge.com/companies/12122">
 Novartis 
 </a>
 , a multi-year partnership agreement with 
 <a href="https://sp-edge.com/companies/36695">
 Illumina 
 </a>
 , an agreement with precision oncology company, 
 <a href="https://sp-edge.com/companies/812083">
 OncoHost 
 </a>
 , 
 and a partnership with 
 <a href="https://sp-edge.com/updates/19329">
 Citagen 
 </a>
 and 
 <a href="https://sp-edge.com/updates/20375">
 Dante Genomics
 </a>
 .&nbsp;
 
 
 Funding and Financials
 
 
 The company began trading on Nasdaq in September 2021 under the ticker symbol &ldquo;SLGC,&rdquo; raising USD 630 million at IPO. For 
 <a href="https://sp-edge.com/updates/17357">
 2022 
 </a>
 revenue increased 20% YoY to USD 97.7 million and the net loss worsened by 24.8% YoY to USD 109.2 million. 
 <a href="https://sp-edge.com/updates/18743">
 In Q1 2023 
 </a>
 , net losses increased considerably by more than 7x YoY to USD 34.2 million while revenue decreased 11% YoY to USD 20.4 million. The company expects revenue for the full-year 2023 in the range of USD 80 million&ndash;84 million, implying a 12%&ndash;17% decrease, excluding licensing revenue from New England Biolabs.
 
</div>

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 
 Peptone claims to have built the world&rsquo;s first protein engineering operating system using AI and quantum computing to develop and engineer proteins by studying the past failures of protein research on a large scale. It focuses on drug discovery against intrinsically disordered proteins (IDPs)&mdash;proteins that lack a fixed or stable 3D structure under physiological conditions, making them flexible and capable of adopting multiple conformations. The company employs cutting-edge structural analysis techniques, such as nuclear magnetic resonance (NMR) spectroscopy, and hydrogen-exchange mass spectrometry (HDX-MS), alongside its proprietary supercomputing capabilities, to simulate and refine potential drug candidates.&nbsp;
 
 
 Peptone's operations are strategically split between its protein biophysics research facility in Bellinzona, Switzerland, and its corporate headquarters in London, UK, utilizing a supercomputer based in Keflavik, Iceland, that runs entirely on renewable energy​​.
 
 
 Key customers and partnerships
 
 
 Peptone has forged a partnership with the 
 <a href="https://www.usi.ch/en/feeds/26628">
 The Institute of Oncology Research
 </a>
 (IOR) in December 2023 to accelerate R&amp;D on treatments for prostate cancer. Prior to that, the company partnered with 
 <a href="https://www.prnewswire.com/news-releases/peptone-announces-a-collaboration-with-nvidia-and-verne-global-to-scale-its-ai-driven-protein-engineering-system-301258885.html">
 NVIDIA and Verne Global
 </a>
 in March 2021 to further enhance its AI drug discovery platform.
 
 
 The company also participated in the Accenture HealthTech Innovation Challenge in November 2017 and secured a partnership with 
 <a href="https://www.linkedin.com/pulse/accenture-selects-peptone-present-ai-driven-system-san-heberling/">
 Accenture
 </a>
 to gain access to the latter's pharmaceutical clients.
 
 
 Funding and financials
 
 
 Peptone secured USD 40 million in a 
 <a href="https://sp-edge.com/updates/11032">
 Series A
 </a>
 funding round led by F-Prime Capital and Bessemer Venture Partners in June 2022 to fuel the construction of a research facility in Bellinzona, Switzerland.
 
</div>

<div>
 
 Flywheel operates a cloud-based medical research data management and collaboration platform which captures and curates clinical data from multiple sources such as imaging, electronic health records (EHRs), digital pathology and omics, to enable further processing and accelerate the drug discovery and development process. Flywheel's cloud platform automates tasks such as handling data and allows scientists to focus on new discoveries. It also offers tools for analyzing and visualizing data and can work with other AI and machine-learning platforms.
 
 
 Key customers and partnerships
 
 
 The company&rsquo;s services are targeted at companies in life sciences, clinical research, imaging research, and AI health development markets. Research institutions such as Stanford University, University of Pennsylvania, University of Michigan, and Massachusetts General Hospital, and Boston Children&rsquo;s Hospital, and Swiss pharma giant Roche and its member company Genentech (
 <a href="https://sp-edge.com/updates/6854">
 November 2021
 </a>
 ) are among its clientele.
 
 
 In 
 <a href="https://sp-edge.com/updates/24331">
 November 2023
 </a>
 , the company collaborated with Microsoft and NVIDIA to launch a SaaS data management solution on Miscrosoft Azure.
 
 
 Funding and financials
 
 
 The company raised USD 54 million In a Series D funding round in June 2023 led by Novalis LifeSciences and NVentures. The proceeds were earmarked to expand its reach into new markets and geographies, especially Europe. 
 
</div>

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

Omada is a prevention-focused digital therapeutics startup that helps members achieve health goals through lifestyle changes. It offers four evidence-based, virtual prevention programs for managing hypertension, musculoskeletal (MSK) issues, prediabetes, and diabetes.Omada offers real-time data tracking through connected devices (such as wireless scales, blood pressure, and glucose monitors) and access to personalized coaching sessions via a mobile app as part of its prevention program. It also provides an online community of peers with similar health conditions to discuss challenges and provide support. In May 2021, Omada became the first fully-virtual healthcare provider to earn the National Committee for Quality Assurance’s Population Health Program Accreditation for its type 2 diabetes and type 2 diabetes + hypertension programs.Unlike its peers, Omada operates a performance-based business model where it charges clients an enrollment fee based on the number of users and a performance fee based on how much weight their employees lose. In May 2020, the company acquired virtual physical therapy startup Physera.Key customers and partnershipsAs of May 2024, Omada had more than 1 million members from more than 1,900 enterprise clients across all 50 US states. Its B2B employer and health plan client base include key clients such as American Eagle, Kaiser Permanente, Costco Wholesale, 3M, and Marvin. Additionally, the company has partnered with health systems and hospitals such as Intermountain Healthcare to provide its preventive programs as a covered benefit.In <a href="https://sp-edge.com/updates/15587">January 2023</a>, the company partnered with health service company Castell (a subsidiary of Intermountain Healthcare) to provide its diabetes programs to members from Intermountain Healthcare’s primary care providers in its Utah Medical Group. Further in <a href="https://sp-edge.com/updates/25245">January 2024</a>, the company partnered with Amazon to expand access to its cardiometabolic program.

Cala Health develops wearable devices that deliver neuromodulation therapies using electrical nerve stimulation. The company claims its FDA-approved Cala Trio is the first non-invasive prescription therapy proven to reduce essential tremors.Its flagship product, the Cala kIQ System, launched in June 2023, uses Transcutaneous Afferent Patterned Stimulation (TAPS) therapy to combat tremors in people with essential tremor and Parkinson’s disease. The device's features include the ability to create individualized stimulation patterns based on the patient's tremor patterns, ease of use as a wrist-worn wearable, and the provision of online data insights via the MyCala.com patient portal that can be shared with healthcare providers.Key customers and partnershipsThe company’s key partners include the University of California, San Francisco to develop next-generation, smart neuromodulation therapies (in June 2021) and SK Biopharmaceuticals to explore new indications in neurology (May 2022).Funding and financialsIn November 2021, Cala Health raised USD 77 million in funding to expand patient access, expedite innovation, and accelerate partnerships with the payers. The proceeds were also used to enhance its product pipeline by adding further neurological conditions such as Parkinson’s disease as well as psychiatry, cardiology, and autoimmune disease therapies.

Artificial intelligence is helping sales teams manage relationships and optimize the customer lifecycle.

Sales Engagement Platforms

Aktana specializes in providing data and intelligence solutions for life sciences industries. Aktana offers the "Contextual Intelligence 360," a modular sales intelligence platform, to scale AI-driven programs that personalize the customer engagement process for life science commercial teams. Its contextual intelligence engine (CIE) uses machine learning (ML) algorithms to plan and arrange multichannel interactions with healthcare providers (HCPs). The platform also features personalized next-best-action recommendations, customer journey mapping tools, automated workflows, a template library, and analytics and reporting. Additionally, it has native integration with customer relationship management (CRM) and marketing automation platforms (MAP) as well as an API for custom integration.The company claims that its solutions improved sales growth by 14% during the indication launch for an innovative oncology drug and a 10% increase in goal attainment for primary care representatives carrying multiple products.In October 2021, The company acquired Ople.AI, a predictive analytics platform, to increase the use and adoption of AI, particularly among developing or mid-market businesses. In November 2023, Aktana acquired Tact.ai, a field engagement and conversational AI platform, to further strengthen its solution.Key customers and partnershipsBy December 2022, it had served 700,000 users across 300+ brands, including over half of the top 20 pharmaceutical firms in the world, such as Pfizer, Janssen, Merck, and Novartis.In September 2022, the company entered into a strategic partnership with Envision Pharma Group, a comprehensive global medical communications group, to provide personalized solutions that blend Envision's scientific expertise and Aktana's intelligence platform for medical affairs teams.

Incorporating technology to improve efficiency and success rate of clinical trials

Clinical Trial Technology

H1 is a provider of several platforms to assist with carrying out clinical trials. The company has four platforms that help with providing insights into different aspects of clinical trials, including key opinion leader identification and engagement, performance, site selection and diversity, data management, and claims-based settlements. In October 2023, the company claimed that its Trial Landscape platform generated insights based on the results of 490,000 trials, 25 million publications, 10 million healthcare providers, 240 million patients, and 11 billion global claims.In <a href="https://sp-edge.com/updates/22479">October 2023</a> the company launched GenosAI, an AI tool embedded into its platform, Trial Landscape. GenosAI offers insights into competing trials, streamlines site selection, promotes diversity in clinical trials, assists with site selection and feasibility assessments, improves trial design, and breaks down data barriers.In <a href="https://sp-edge.com/updates/35540">Octber 2024</a>, H1 expanded its Trial Landscape platform by integrating diversity data for over 34 million patients in England and launching an AI-powered Site Rescue functionality. The updates were made available to Trial Landscape clients with the global data package. The expanded platform included race and ethnicity data from UK patients and features Site Rescue, an AI-powered tool that identifies healthcare providers, sites, and principal investigators based on historical performance data.&nbsp;&nbsp;

Transforming neurological care with innovation

Neurostimulation Tech

Cala Health is a bioelectronic medicine company that has developed the Cala kIQ system, a wearable neuromodulation device that delivers transcutaneous afferent patterned stimulation (TAPS) therapy for the relief of hand tremors in adults with essential tremor and Parkinson's disease. The Cala kIQ system comprises a stimulator, a band with integrated electrodes, and a base station. It utilizes a calibrated TAPS output pattern adjusted to match the patient's unique tremor frequency, providing personalized stimulation to the median and radial nerves of the wrist.
The Cala kIQ system received 510k clearance from the US Food and Drug Administration (FDA) in November 2022 and was launched for human use in June 2023. The device offers treatment sessions of 40 minutes, with a wristband life of 90 days and a shelf life of three months. Patients can review their therapy session results through the MyCala.com patient portal and share them with healthcare providers.
Cala Health has reported positive clinical data demonstrating the effectiveness of TAPS therapy in reducing tremors and improving activities of daily living for essential tremor patients. The company has secured reimbursement and coding from various commercial and government payors, including Medicare, to improve patient access to the therapy.

We are the first in class pre-clinical translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered targets.

Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients to get better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective services for payors.

H1 provides a global healthcare platform to help life sciences companies, hospitals, academic medical centers, and health systems connect with providers, find clinical research, locate industry experts, and benchmark their organizations. As the trusted source of information on healthcare professionals and institutions, H1 connects the entire healthcare ecosystem through real-time data and clinical findings.  Founded in 2017, the company is based in New York, United States.

Science 37 is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, the company provides access to patients who can never be reached by traditional site-based research models. Its virtual model has proven to enroll faster, retain patients at a higher rate, and reach a more representative patient population. Science 37 has conducted more virtual (or decentralized), interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses. The company's research is powered by the industry’s most comprehensive, fully integrated clinical trial platform purpose-built to conduct virtual trials.

Flywheel is a data management and analysis platform built specifically for scientists and the researcher's workflow.  They empower research momentum by focusing on data and medical image capture, content management, scientific computation, and collaboration.  With reproducible research in mind, they combine open-source methods from top universities, a modern web user interface, and an extensible compute engine based on containerization technology. The result is a software platform to accelerate discovery and help researchers do science, not IT. Flywheel accelerates new scientific discoveries in life-science, biotech, and academic imaging research through cloud-scale collaboration. As a result, imaging researchers are able to avoid innovation bottlenecks, and accelerate discovery by doing more science, and less IT.

Dopavision is a therapeutic company developing a digital therapeutic for myopia. Myopia, or shortsightedness, is a condition where the visual image is focused in front of the retina, instead of on the retina itself, as it should. People with myopia have good near sight vision but poor distance vision. Dopavision is developing a digital therapeutic for myopia which can be seamlessly and invisibly integrated with the use of a smartphone. Myopia is a visual condition that affects on average every third person globally, a share that has increased rapidly during the last two decades.  The goal of the Berlin-based startup is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Founded in 2017, Dopavision GmbH is supported by the German government via the “Industrie-in-Klinik” program of the BMBF (Federal Ministry of Education and Research) with the amount of € 1.4 million over three years.

Aspen RxHealth is a service powered by an app-based platform that connects pharmacists with patients in need of enhanced medication services. Its application makes it easy for health plans and providers to connect their patients with an on-demand community of pharmacists who have time and expertise to provide clinical service.

Koneksa Health is a healthcare data analytics company that helps researchers incorporate emerging technologies (bio-sensors, activity trackers, mobile-based questionnaires, etc.) into their clinical studies. Their Koneksa Compare software dashboard enables the collection, visualization, and analysis of these patient-generated data sets. Koneksa currently supports academic and life sciences researchers, expands the universe of data that can be analyzed while also removing subjective characteristics from clinical endpoints. It was founded in 2015 and is based in New York, United States.

Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies. The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine. Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.

Animantis develop and apply computational tools to comprehensively characterize cellular function to guide the future of medicine.

RxVantage is OpenTable.com for pharma reps (and other medical vendors) looking to access physicians.  The company's cloud-based platform improves patient outcomes and enhances the relationship between medical representatives and physicians’ offices.   The Problem:  The pharmaceutical industry spends $60 billion per year marketing, most of which is directed to the physicians who determine how the $325 billion that Americans spend each year on prescription drugs will be allocated. These marketing dollars go toward reaching docs at the point of care via sales reps that provide free samples and educational materials for patients, and medical education to doctors and their staff. All pharma brands must be in the practice if they hope to succeed.  The last decade has seen an explosion of novel medical technologies and treatments, along with a corresponding increase in the number of reps promoting them. More than 130,000 reps visit the 30,000 busiest medical practices every day. These practices see value in what individual reps deliver, however, they are often overwhelmed by a community of reps that cannot organize itself to fit the practices’ schedules and priorities.    In an attempt to control the rep chaos, these practices often dedicate hundreds of staff hours per year to coordinating rep visits on handwritten paper calendars and business cards. With pharma having demonstrated more than a 1000% ROI on such visits, far higher than any other sales/marketing channel, demand for access far outstrips supply.  Despite this high demand, more than 30% of these appointments are abandoned by the scheduled rep and go unfilled, a paradox that occurs because:  1. Appointments are booked up to one year in advance by reps that must be in the practice. 2. Rep turnover is high, and territories and physician targets are constantly realigned. 3. Appointment information is locked inside tens of thousands of individual paper calendars.  Unfortunately, the burden on staff time and the high rate of “no-show” appointments can lead a practice to reduce rep access to their doctors, or, eliminate it all together. As a result, the most effective channel pharma has to educate doctors about new treatments is becoming a victim of its own success.   Enter RxVantage:  Our technology enables practices to control the flow of reps in their office without utilizing staff time, which can then be re-focused on patients. Putting the practice back in control empowers them to remain open to receiving the valuable education and services that reps provide. This is especially important given studies showing that physicians not seeing reps are 4X slower to react to new information, both positive (i.e. new standard of care) and negative (i.e. product recall).  In addition to keeping the practices’ doors open, RxVantage creates more opportunities for reps within each practice. By freeing the appointment data from the cages of the paper calendars, we apply our innovative technology to every appointment in order to predict and eliminate “no-shows” before they happen. By enabling other reps to book these appointments that otherwise would have been wasted, RxVantage makes the sales forces that call on our medical practices 30% more productive.  More than 11,000 reps from 400 companies have used RxVantage to book over 120,000 appointments with 1,200 practices containing 4,000 high-prescribing physicians. At this scale the company has created more than $100MM in value for pharma by virtue of the 40,000+ appointments that would not have occurred in the absence of our technology. In the next 18 months, as new financing allows us to ramp this proven sales process and support the channel partnerships that we have negotiated, the value we create for pharma will exceed $1BB across a network that includes 50,000 physicians.  The RxVantage platform includes a dedicated online medical rep scheduling calendar, a communication hub that enables practices to efficiently interact with reps, a sample request tool, up-to-date directory of patient assistance programs, and a drug coupon database.

Freenome is a biotech company developing accurate, accessible, and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. The company is developing a simple blood test to detect early-stage cancer and make treatments more effective and provides a platform that helps design healthy conditions for an individual based on his/her cell-free genome. The company aims to reinvent disease management through systematized early detection and intervention.

Xealth scales digital health programs, enabling clinicians to integrate, prescribe and monitor digital health tools for patients to drive engagement and utilization. Through the secure Xealth platform, clinicians can find and order the right digital health tools and programs for patients directly from the EHR workflow, send these digital health orders to the patient’s email or patient portal, and then monitor activity.

Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its vertically integrated commercial model is reshaping the delivery of prescription therapies. Cala Health’s lead product, Cala Trio™ therapy, is the only non-invasive prescription therapy for essential tremor. New therapies are under development in Parkinson’s disease and other indications in neurology, as well as targets in psychiatry, cardiology, and autoimmune disorders. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.

SchoolCare delivers free health technology for K-12 public schools to help school nurses deliver care and keep students safe. It is a digital health platform for the largest and most consistent health delivery system in the country. Their mission is to work with partners to provide a unified health record for every family.  SchoolCare leverages pediatric health data and this country’s most successful public health organization, the K-12 school system, to improve outcomes and learn about clinical health data outside of the provider’s office.  Traditional care coordination stops short of sending essential care instructions to School Nurses and thus increases the risk of stopped or inconsistent post-discharge care delivery. By closing the link in the pediatric care continuum, children stay healthy and get better faster.

Aktana helps life science companies get the most out of artificial intelligence for commercializing their products. Its platform harnesses machine learning algorithms to enable marketing and sales teams to optimize their engagement with prescribing physicians. Aktana supports more than 100 brands and more than half the top 20 pharmaceutical companies worldwide to increase revenue, capitalize on data investments, and drive channel productivity and results.  The company’s focus on the life sciences market allows Aktana to understand and incorporate unique market dynamics more deeply than the major AI players. Headquartered in San Francisco, Aktana also has offices in New York, Philadelphia, London, Barcelona, Tokyo, Osaka, and Shanghai.

Mekonos creates a proprietary cell-engineering platform designed for cell therapies on a chip.  Mekonos is a Silicon Valley Venture-backed technology company — creating a proprietary cell-engineering platform based on scalable silicon technology for our partners engaged in drug discovery and development.

COTA was founded in 2011 by doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real world data. By using proprietary technology, advanced analytics and deep expertise to organize complex data, COTA provides a comprehensive picture of cancer that can be used to advance care and research.

Omada Health is a digital care company that offers innovative and clinically effective digital health programs to empower individuals to engage in their health and lead healthier lives. The program is personalized to meet each participant’s unique needs as they evolve, ranging from diabetes prevention, type 2 diabetes management, hypertension, behavioral health, and musculoskeletal issues. Omada combines professional health coaching, connected health devices, real-time data, and personalized feedback to deliver clinically meaningful results. The company is the largest CDC-recognized provider of the National Diabetes Prevention Program.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions.  SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

Founded in 2015, dRx Capital is Novartis' Digital Health Venture Fund investing in entrepreneurs transforming healthcare through data and digital technology. The fund invests in technology platforms improving access to healthcare and reimagining the practice of medicine, with a focus on AI & ML, big data, R&D optimization, patient care, and pharma supply chain and commercialization.

dRx Capital

Portfolio

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless